

CORPORATE EVENTS

MEMO # 10-245

DATE: 6/9/10

ACTION:

On June 7, 2010, Ruby Acquisition, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., a wholly-owned subsidiary of Astellas Pharma Inc., completed its Subsequent Tender Offer for OSI Pharmaceuticals, Inc. (OSIP) Common Shares. The merger was subsequently consummated on June 8, 2010. As a result, each existing OSIP Common Share will be converted into the right to receive \$57.50 net cash per share.

This action will be coordinated with the Options Clearing Corporation.

CATEGORY:

Merger

EQUITY SYMBOL:

OSI Pharmaceuticals, Inc. (OSIP)

ONE CHICAGO SYMBOL:

OSIP1C

CME FUTURES SYMBOL:

L4

MULTIPLIER:

100 (e.g., 1.00 equals \$100.00)

EFFECTIVE DATE:

Thursday, June 10, 2010

NEW DELIVERABLE PER CONTRACT:

\$5,750 (\$57.50 x 100 Common Shares)

APPLICABLE CONTRACT MONTHS:

June, July, September, December 2010

SETTLEMENT PRICES AND POSITIONS:

The underlying price for the OSIP1C Futures contract deliverable, expressed in term of current market value, would be calculated as follows:

OSIP1C = 57.50

NOTES:

The forecasted effect of the upcoming corporate event on each clearing firms' positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report (ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).

If you have any questions regarding the information provided in the document, please call CME Clearing risk management hotline at (312) 648-3888.